Prevalence and risk factors of Gram-negative bacilli causing blood stream infection in patients with malignancy

References

1. ↵
   1. Arnan M,
   2. Gudiol C,
   3. Calatayud L,
   4. Liñares J,
   5. Dominguez MÁ,
   6. Batlle M,
   7. et al.

   (2011) Risk factors for, and clinical relevance of, faecal extended-spectrum ß-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 30:355–360.

   OpenUrlCrossRefPubMed
2. ↵
   1. Wojak I,
   2. Gospodarek E

   (2004) Analysis of microorganisms isolated from febrile neutropenic children with neoplastic disease. Med Dosw Mikrobiol 56:411–419.

   OpenUrlPubMed
3. ↵
   1. Haupt R,
   2. Romanengo M,
   3. Fears T,
   4. Viscoli C,
   5. Castagnola E

   (2001) Incidence of septicaemias and invasive mycoses in children undergoing treatment for solid tumours: a 12-year experience at a single Italian institution. Eur J Cancer 37:2413–2419.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Fridkin SK,
   2. Gaynes RP

   (1999) Antimicrobial resistance in intensive care units. Clin Chest Med 20:303–316.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Eltahawy AT

   (2003) Febrile neutropenia Etiology of infection, empirical treatment and prophylaxis. Saudi Med J 24:331–336.

   OpenUrlPubMed
6. 1. Babay HA

   (2007) Bacterial isolates from fatal cases of bloodstream infections at a university hospital in Central, Saudi Arabia. Saudi Med J 28:231–235.

   OpenUrlPubMed
7. 1. Mansoor Sirkhazi,
   2. Azmi Sarriff,
   3. Noorizan Abd Aziz,
   4. Fatma Almana,
   5. Osama Arafat,
   6. Mahmoud Shorman

   (2014) Bacterial Spectrum, Isolation Sites and Susceptibility Patterns of Pathogens in Adult Febrile Neutropenic Cancer Patients at a Specialist Hospital in Saudi Arabia. World J Oncol 5:196–203.

   OpenUrl
8. ↵
   1. Al-Ahwal MS

   (2005) Pattern of febril neutropenia in solid tumors - A hospital based study. Pak J Med Sic 21:249–252.

   OpenUrl
9. ↵
   1. Glasmacher A,
   2. Von Lilienfeld-Toal M,
   3. Schulte S,
   4. Hahn C,
   5. Schmidt-Wolf IG,
   6. Prentice A

   (2005) An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 11:17–23.

   OpenUrlCrossRef
10. ↵
    1. Reuben AG,
    2. Musher DM,
    3. Hamill RJ,
    4. Broucke I

    (1989) Polymicrobial bacteremia: clinical and microbiologic patterns. Rev Infect Dis 11:161–183.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. National Committee for Clinical Laboratory Standards

    (2000) Tenth informational supplement M100-S10, Performance Standards for Antimicrobial Susceptibility Testing (National Committee for Clinical Laboratory Standards, Wayne, PA).
12. ↵
    1. Magiorakos AP,
    2. Srinivasan A,
    3. Carey RB,
    4. Carmeli Y,
    5. Falagas ME,
    6. Giske CG,
    7. et al.

    (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281.

    OpenUrlCrossRefPubMed
13. ↵
    1. Gudiol C,
    2. Calatayud L,
    3. Garcia-Vidal C,
    4. Lora-Tamayo J,
    5. Cisnal M,
    6. Duarte R,
    7. et al.

    (2010) Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65:333–341.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    1. Gudiol C,
    2. Tubau F,
    3. Calatayud L,
    4. Garcia-Vidal C,
    5. Cisnal M,
    6. Sanchez-Ortega I,
    7. Duarte R,
    8. et al.

    (2011) Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 66:657–663.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Moghnieh R,
    2. Estaitieh N,
    3. Mugharbil A,
    4. Jisr T,
    5. Abdallah DI,
    6. Ziade F,
    7. et al.

    (2015) Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis. Front Cell Infect Microbiol 5:11.

    OpenUrl
16. ↵
    1. Irfan S,
    2. Idrees F,
    3. Mehraj V,
    4. Habib F,
    5. Adil S,
    6. Hasan R

    (2008) Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 8:80.

    OpenUrlCrossRefPubMed
17. ↵
    1. Samonis G,
    2. Vardakas KZ,
    3. Maraki S,
    4. Tansarli GS,
    5. Dimopoulou D,
    6. Kofteridis DP,
    7. et al.

    (2013) A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer 21:2521–2526.

    OpenUrlCrossRefPubMed
18. ↵
    1. Musollino G,
    2. Mastrolonardo G,
    3. Prezioso R,
    4. Pagano L,
    5. Primignani P,
    6. Carestia C,
    7. et al.

    (2012) Molecular mechanisms of a novel ß-thalassaemia mutation due to the duplication of tetranucleotide ‘AGCT’at the junction IVS-II/exon 3. Ann Hematol 91:1695–1701.

    OpenUrlPubMed
19. ↵
    1. Montassier E,
    2. Batard E,
    3. Gastinne T,
    4. Potel G,
    5. deLaCochetière MF

    (2013) Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis 32:841–850.

    OpenUrlCrossRefPubMed
20. ↵
    1. Pagano L,
    2. Caira M,
    3. Trecarichi EM,
    4. Spanu T,
    5. Di Blasi R,
    6. Sica S,
    7. et al.

    (2014) Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis 20:1235–1236.

    OpenUrlCrossRefPubMed
21. ↵
    1. Kang CI,
    2. Chung DR,
    3. Ko KS,
    4. Peck KR,
    5. Song JH,
    6. Korean Network for Study of Infectious Diseases

    (2012) Risk factors for infection and treatment outcome of extended-spectrum ß-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 91:115–121.

    OpenUrlCrossRefPubMed
22. ↵
    1. Trecarichi EM,
    2. Tumbarello M,
    3. Spanu T,
    4. Caira M,
    5. Fianchi L,
    6. Chiusolo P,
    7. Fadda G,
    8. Leone G,
    9. Cauda R,
    10. Pagano L

    (2009) Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58:299–307.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    1. Kang CI,
    2. Chung DR,
    3. Ko KS,
    4. Peck KR,
    5. Song JH

    (2011) The Korean Network for the Study of Infectious Diseases (KONSID). Risk factors for mortality and impact of broad-spectrum cephalosporin resistance on outcome in bacteraemic intra-abdominal infections caused by Gram-negative bacilli. Scand J Infect Dis 43:202–208.

    OpenUrlPubMed
24. ↵
    1. Gudiol C,
    2. Carratala J,
    3. Antibiotic resistance in cancer patients

    (2014) Expert Rev Anti Infect Ther. Expert Rev Anti Infect Ther 12:1003–1016.

    OpenUrlCrossRef
25. ↵
    1. Chong Y,
    2. Yakushiji H,
    3. Ito Y,
    4. Kamimura T

    (2010) Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies. Int J Infect Dis 14(Suppl 3):e171–e175.

    OpenUrlPubMed
26. ↵
    1. Trecarichi EM,
    2. Tumbarello M,
    3. Spanu T,
    4. Caira M,
    5. Fianchi L,
    6. Chiusolo P,
    7. Fadda G,
    8. et al.

    (2009) Incidence a nd clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58:299–307.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    1. Khan MA,
    2. Siddiqui BK,
    3. Shamim A,
    4. Yosuf MA,
    5. Ahmed A,
    6. Zakiullah N,
    7. et al.

    (2004) Emerging bacterial resistance pattern in febrile neutropenic patients: experience at a tertiary care hospital in Pakistan. J Pak Med Assoc 54:357–360.

    OpenUrlPubMed
28. ↵
    1. Hamzeh F,
    2. Kanj SS,
    3. Uwaydah M

    (2000) Febrile neutropenia in cancer patients in a tertiary care medical center in Lebanon: microbial spectrum and outcome. J Med Liban 48:136–142.

    OpenUrlPubMed
29. ↵
    1. Kanafani ZA,
    2. Dakdouki GK,
    3. El-Chammas KI,
    4. Eid S,
    5. Araj GF,
    6. Kanj SS

    (2007) Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade. Int J Infect Dis 11:450–453.

    OpenUrlCrossRefPubMed
30. ↵
    1. Khan MA,
    2. Siddiqui BK,
    3. Shamim A,
    4. Yosuf MA,
    5. Ahmed U,
    6. Zakiullah N,
    7. et al.

    (2004) Emerging bacterial resistance patterns in febrile neutropenic patients: experience at a tertiary care hospital in Pakistan. J Pak Med Assoc 54:357–360.

    OpenUrlPubMed
31. 1. Cherif H,
    2. Bjorkholm M,
    3. Engervall P,
    4. Johansson P,
    5. Ljungman P,
    6. Hast R,
    7. et al.

    (2004) A prospective, randomized study comparing cefepime and imipenem--cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 36:593–600.

    OpenUrlCrossRefPubMedWeb of Science
32. ↵
    1. Rossini F,
    2. Terruzzi E,
    3. Verga L,
    4. Larocca A,
    5. Marinoni S,
    6. Miccolis I,
    7. et al.

    (2005) A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. Support Care Cancer 13:387–392.

    OpenUrlCrossRefPubMedWeb of Science